OncoMatch/Clinical Trials/NCT05798897
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Is NCT05798897 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MT-601 for non-hodgkin lymphoma, adult.
Treatment: MT-601 — This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Performance status
KARNOFSKY/ECOG 0–1
Karnofsky score of ≥70 or performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
Prior therapy
Cannot have received: allogeneic hematopoietic cell transplant
Receipt of allogeneic hematopoietic cell transplant (HCT) within 12 months; on immunosuppression or with evidence of donor/mixed chimera
Cannot have received: autologous hematopoietic cell transplant
Receipt of autologous HCT within 3 months
Cannot have received: CD19-directed CAR T cell therapy
Treatment with CD19-directed CAR T cell therapy within 3 months
Cannot have received: bispecific antibody
Treatment with bispecific antibody within 1 month
Cannot have received: antibody-drug conjugate
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: anti-PD-1 therapy
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: anti-PD-L1 therapy
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: monoclonal antibodies impacting T cell function
Treatment with monoclonal antibodies impacting T cell function within 14 days
Cannot have received: systemic immunosuppression (systemic corticosteroids)
Exception: unless ≤5 mg/day oral prednisone or steroid equivalent
Treatment with systemic immunosuppression including systemic corticosteroids (unless ≤5 mg/day oral prednisone or steroid equivalent) within 14 days
Cannot have received: chemotherapy
Treatment with chemotherapy within 7 days
Cannot have received: live, attenuated vaccine
Treatment with a live, attenuated vaccine within 4 weeks
Cannot have received: antibody-drug conjugate
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: anti-PD-1 therapy
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: anti-PD-L1 therapy
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: chemotherapy
Treatment with chemotherapy or biologics/monoclonal antibodies within 14 days
Cannot have received: biologics/monoclonal antibodies
Treatment with chemotherapy or biologics/monoclonal antibodies within 14 days
Cannot have received: radiation therapy
Treatment with radiation therapy within 7 days
Cannot have received: tyrosine kinase inhibitor
Treatment with a tyrosine kinase inhibitor (TKI) within 7 days or 5 half-lives (whichever is longer) before conditioning regimen
Cannot have received: hematopoietic growth factors
Hematopoietic growth factors <2 days
Cannot have received: experimental CAR T cell product
Exception: unless approved by Medical Monitor
Treatment with experimental CAR T cell product unless approved by Medical Monitor
Cannot have received: other cancer therapy including investigational agents
Treatment with other cancer therapy including investigational agents that do not fit in the above categories within 14 days
Cannot have received: major surgery
Major surgery within 14 days
Lab requirements
Blood counts
Hemoglobin ≥ 7.0 g/dL (can be transfused), ALC ≥ 300/μL (prior to apheresis only), ANC ≥ 750/μL and platelet count ≥ 50,000/μL (prior to the conditioning regimen only)
Kidney function
Serum creatinine ≤ 1.5X ULN or measured or calculated creatinine clearance ≥ 50 mL/min (prior to the conditioning regimen)
Liver function
Bilirubin ≤ 1.5X ULN (exception of bilirubin elevation due to Gilbert's syndrome 3X); AST and ALT ≤ 3X ULN
Cardiac function
left ventricular ejection fraction ≥ 45% (prior to the leukapheresis)
Adequate blood, liver, renal and cardiac function: Hemoglobin ≥ 7.0 g/dL (can be transfused), ALC ≥ 300/μL (prior to apheresis only), ANC ≥ 750/μL and platelet count ≥ 50,000/μL (prior to the conditioning regimen only); Bilirubin ≤ 1.5X ULN (exception of bilirubin elevation due to Gilbert's syndrome 3X); AST and ALT ≤ 3X ULN; Serum creatinine ≤ 1.5X ULN or measured or calculated creatinine clearance ≥ 50 mL/min (prior to the conditioning regimen); left ventricular ejection fraction ≥ 45% (prior to the leukapheresis)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- University of Colorado · Aurora, Colorado
- Colorado Blood Cancer Institute (Sarah Cannon) · Denver, Colorado
- University of Kansas Medical Center · Kansas City, Kansas
- Cornell · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify